Compare Archer-Daniels-Midland Co (ADM) vs Novavax Inc (NVAX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Archer-Daniels-Midland Co vs Novavax Inc — how do they compare? Archer-Daniels-Midland Co trades at $79.94 (market cap $37.69B), while Novavax Inc trades at $9.43 (market cap $1.56B). The key difference: Archer-Daniels-Midland Co is far larger — about 24.2× Novavax Inc's market cap, and Archer-Daniels-Midland Co pays a 2.66% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| ADM | NVAX | |
|---|---|---|
Market Cap | $37.69B | $1.56B |
Sector | Consumer Staples | Health |
52-Week High | $84.11 | $11.19 |
52-Week Low | $53.54 | $6.22 |
Enterprise Value | $47.72B | $1.06B |
Dividend Yield | 2.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $78.20, up 1.84% recently, with a bullish technical signal from moving averages and a consensus analyst price target of $78.00. The company has beaten EPS estimates for three consecutive quarters, though revenue has declined from $101.6B in 2022 to $80.3B in 2025. Net cash flow improved to $1.58B in 2025, reversing negative trends from prior years, while the stock shows a P/E of 34.79 and P/S of 0.47, indicating mixed valuation signals.
Outlook is cautiously optimistic with strong cash flow and earnings beats, but risks include declining revenue margins and competitive pressures. The stock offers value characteristics with a low P/S ratio, yet investors face headwinds from narrowing profit margins and global trade volatility in agricultural markets.
Novavax (NVAX) trades at $9.46, down 2.87% on the day, with a bullish technical signal from moving averages. The company reported strong revenue of $1.12B in 2025 and has beaten EPS estimates for three consecutive quarters. Analyst consensus is bullish with a $14.00 price target, though negative cash flow and shareholder equity remain concerns. Recent news highlights investor attention and participation in healthcare conferences.
Outlook: Potential upside exists from continued earnings beats and vaccine demand, but risks include persistent cash burn, high debt, and competitive pressures. The stock offers speculative growth opportunity amid volatile biotech sentiment, requiring careful risk assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
